Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL9514623 | 0.96 | SIGMAR1 (0.55) | GAAALOX12LMNATDP1TSHR | |
| SCHEMBL813710 | 0.81 | KMT2A (0.79) | TDP1TSHRKMT2AMEN1HTT | |
| SCHEMBL6719364 | 0.80 | HTT (0.51) | LMNASIGMAR1KMT2AMEN1HTT | |
| SCHEMBL2751737 | 0.79 | KMT2A (0.76) | TDP1TSHRKMT2AMEN1HTT | |
| Ditolylguanidine SCHEMBL30468948 | 0.77 | NPC1 (0.61) | ALOX12LMNATSHRSIGMAR1KMT2A | |
| Ditolylguanidine SCHEMBL35348 | 0.77 | NPC1 (0.61) | ALOX12LMNATSHRSIGMAR1KMT2A | |
| SCHEMBL9082358 | 0.77 | ALOX12 (0.56) | GAAALOX12LMNATSHRKMT2A | |
| SCHEMBL11267805 | 0.76 | ALOX12 (0.62) | GAAALOX12LMNATSHRKMT2A | |
| Ditolylguanidine SCHEMBL34468120 | 0.75 | NPC1 (0.59) | ALOX12LMNATSHRSIGMAR1KMT2A | |
| Ditolylguanidine SCHEMBL28288690 | 0.75 | NPC1 (0.59) | ALOX12LMNATSHRSIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040817-B1 | Dyeing composition comprising a pyrazolo(1,5-a)pyrimidine and a monocyclic polyaminopyrimidine as oxidation bases and a coupler, and dyeing process | OREAL (FR) | 2005-02-02 | — | — | EP | claimed |
| EP-1030645-B1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | OREAL (FR) | 2004-05-12 | — | — | EP | claimed |
| EP-1030646-B1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | OREAL (FR) | 2004-04-28 | — | — | EP | claimed |
| EP-1030648-B1 | DYEING COMPOSITION CONTAINING A PYRAZOLO- 1,5-a]-PYRIMIDINE AS OXIDATION BASE AND A PYRIDINE COUPLING AGENT, AND DYEING METHOD | OREAL (FR) | 2003-12-03 | — | — | EP | claimed |
| EP-1030647-B1 | DYEING COMPOSITION CONTAINING A PYRAZOLO- 1,5-a]-PYRIMIDINE AS OXIDATION BASE AND A NAPHTHALENE COUPLING AGENT, AND DYEING METHOD | OREAL (FR) | 2003-12-03 | — | — | EP | claimed |
| EP-0988021-B1 | KERATIN FIBRE OXIDATION DYEING COMPOSITION AND DYEING METHOD USING SAME | OREAL (FR) | 2003-11-12 | — | — | EP | claimed |
| EP-0994692-B1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES CONTAINING A 3-AMINOPYRIDINE AZO DERIVATIVE AND DYEING METHOD USING SAID COMPOSITION | OREAL (FR) | 2003-04-23 | — | — | EP | claimed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| EP-0847271-B1 | PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE | OREAL (FR) | 2002-05-02 | — | — | EP | claimed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | claimed |
| US-5385946-A | Method for treating hypertension with disubstituted granidine compounds | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1995-01-31 | — | — | US | claimed |
| EP-0473671-B1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT | OREGON STATE (US) | 1994-08-24 | — | — | EP | claimed |
| US-5312840-A | Substituted guanidines having high binding to the sigma receptor and the use thereof | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION (US) | 1994-05-17 | — | — | US | claimed |
| EP-0314690-B1 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE | OREGON STATE (US) | 1993-12-29 | — | — | EP | claimed |
| EP-0473671-A4 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | — | 1992-04-01 | — | — | EP | claimed |
| EP-0473671-A1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT. | OREGON STATE (US) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014067-A2 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-29 | — | — | WO | claimed |
| EP-0314690-A4 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE. | OREGON STATE (US) | 1989-11-07 | — | — | EP | claimed |
| EP-0314690-A1 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE. | OREGON STATE (US) | 1989-05-10 | — | — | EP | claimed |
| WO-1988000583-A1 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE | STATE OF OREGON ACTING BY AND THROUGH THE STATE BO (US) | 1988-01-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | GAA 2268/4885ALOX12 255/4885LMNA 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.